1 Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal 2 limited infectious virus shedding and restricted tissue distribution

- 3
- Ruian Ke^{1#}, Pamela P. Martinez^{2,3,4#}, Rebecca L. Smith^{4,5,6}, Laura L. Gibson⁷, Chad J. 4
- 5 Achenbach^{8,9}, Sally McFall^{10,11}, Chao Qi¹², Joshua Jacob⁸, Etienne Dembele⁸, Camille Bundy¹³,
- Lacy M. Simons^{8,9}, Egon A. Ozer^{8,9}, Judd F. Hultquist^{8,9}, Ramon Lorenzo-Redondo^{8,9}, Anita K. 6
- Opdycke¹⁴, Claudia Hawkins^{8,9}, Robert L. Murphy^{8,9}, Agha Mirza¹⁵, Madison Conte¹⁵, Nicholas 7
- Gallagher¹⁶, Chun Huai Luo¹⁶, Junko Jarrett¹⁶, Abigail Conte¹⁷, Ruifeng Zhou¹⁷, Mireille Farjo², 8
- Gloria Rendon¹⁸, Christopher J. Fields¹⁸, Leyi Wang¹⁹, Richard Fredrickson¹⁹, Melinda E. Baughman⁴, Karen K. Chiu⁴, Hannah Choi⁴, Kevin R. Scardina⁴, Alyssa N. Owens²⁰, John 9
- 10
- Broach^{21,22}, Bruce Barton^{23,24}, Peter Lazar²³, Matthew L. Robinson¹⁵, Heba H. Mostafa¹⁶, Yukari 11
- C. Manabe^{15,17}, Andrew Pekosz¹⁷, David D. McManus²⁵, Christopher B. Brooke^{2,4*} 12
- 13
- 14 ¹T-6, Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 15 87545, USA
- 16 ² Department of Microbiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, 17 USA
- 18 ³ Department of Statistics, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
- 19 ⁴ Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign,
- 20 Urbana, IL 61801, USA
- 21 ⁵ Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, 22 USA
- 23 ⁶ Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 24 61801, USA
- 25 ⁷ Division of Infectious Diseases and Immunology, Departments of Medicine and Pediatrics, 26 University of Massachusetts Medical School, Worcester, MA 01655, USA
- 27 ⁸ Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, IL 28 60611, USA
- 29 ⁹ Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg 30 School of Medicine, Chicago, IL 60611, USA
- 31 ¹⁰ Center for Innovation in Point-of-Care Technologies for HIV/AIDS at Northwestern University, 32 Evanston, IL 60208, USA
- 33 ¹¹ Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA
- 34 ¹² Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 35 60611. USA
- 36 ¹³ Institute for Sexual and Gender Minority Health and Wellbeing, Northwestern University
- 37 Feinberg School of Medicine, Chicago, IL 60611, USA
- 38 ¹⁴ Department of Health Service, Northwestern University, Evanston, IL 60208, USA
- 39 ¹⁵ Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, 40 Baltimore, MD 21287, USA
- 41 ¹⁶ Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School
- 42 of Medicine, Baltimore, MD 21287, USA
- 43 ¹⁷W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA 44
- 45 ¹⁸ High-Performance Biological Computing at the Roy J. Carver Biotechnology Center,
- 46 University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
- 47 ¹⁹Veterinary Diagnostic Laboratory, University of Illinois at Urbana-Champaign, Urbana, IL

48 61802. USA

- ²⁰ Center for Clinical and Translational Research, University of Massachusetts Medical School, 49
- 50 Worcester, MA 01655, USA

- 51 ²¹ UMass Memorial Medical Center, Worcester, MA 01655, USA
- ²² Department of Emergency Medicine, University of Massachusetts Medical School, Worcester,
 MA 01655, USA
- ²³ Division of Biostatistics and Health Services Research, University of Massachusetts Medical
 School, Worcester, MA 01655, USA
- ²⁴ Department of Population and Quantitative Health Sciences, University of Massachusetts
 Medical School, Worcester, MA 01655, USA
- ²⁵ Division of Cardiology, University of Massachusetts Medical School, Worcester, MA 01655,
 USA
- 60 [#] These authors contributed equally
- 61 * Corresponding author (cbrooke@illinois.edu)
- 62

63 ABSTRACT

- 64 The global effort to vaccinate people against SARS-CoV-2 in the midst of an ongoing
- 65 pandemic has raised questions about the nature of vaccine breakthrough infections and
- 66 the potential for vaccinated individuals to transmit the virus. These questions have
- 67 become even more urgent as new variants of concern with enhanced transmissibility,
- 68 such as Delta, continue to emerge. To shed light on how vaccine breakthrough
- 69 infections compare with infections in immunologically naive individuals, we examined
- viral dynamics and infectious virus shedding through daily longitudinal sampling in a
- small cohort of adults infected with SARS-CoV-2 at varying stages of vaccination. The
- durations of both infectious virus shedding and symptoms were significantly reduced in
- vaccinated individuals compared with unvaccinated individuals. We also observed that
- 74 breakthrough infections are associated with strong tissue compartmentalization and are
- only detectable in saliva in some cases. These data indicate that vaccination shortens
- the duration of time of high transmission potential, minimizes symptom duration, and
- 77 may restrict tissue dissemination.

78

79 MAIN TEXT

- 80 Licensed vaccines against SARS-CoV-2 have already established a clear record of
- 81 success in reducing case numbers and disease severity in areas that have achieved
- 82 high vaccination rates. While vaccination clearly limits susceptibility to the virus,
- 83 breakthrough infections can occur, as no vaccines are capable of eliciting sterilizing
- 84 immunity, particularly against viruses that infect mucosal tissues¹. Characterizing the
- 85 unique features of breakthrough infections is critical for evaluating the potential for
- 86 vaccinated individuals to transmit virus and understanding how vaccine-induced
- 87 immunity suppresses viral replication and mitigates disease severity.
- 88
- A study performed in Israel estimated that vaccination with the BNT162b2
- 90 (Pfizer/BioNTech) mRNA vaccine substantially reduced the potential for transmission
- 91 among household contacts². Other recent data have suggested that vaccinated
- 92 individuals may shed virus (as measured by RTqPCR) at similar levels to unvaccinated
- 93 individuals, particularly when infected with the Delta variant^{3–5}. Some interpretations of
- 94 these preliminary studies have suggested that the risk for secondary transmission is
- 95 similar for vaccinated and unvaccinated individuals. However, most studies to date base
- 96 their conclusions on cross sectional sampling of viral genome loads (as measured by
- 97 RTqPCR), which may not directly translate to infectiousness⁶. In a cohort of

- 98 longitudinally sampled participants who screened positive for SARS-CoV-2, we
- 99 previously showed that the relationship between viral genome load and infectious virus
- 100 load can vary greatly across individuals and over time, making the use of cross-
- 101 sectional RTqPCR data problematic for estimations of infectiousness⁷. Therefore,
- 102 longitudinal comparisons of viral genome shedding and infectious virus shedding across
- 103 tissue compartments between vaccinated and unvaccinated individuals are needed to
- 104 more accurately assess the effects of vaccination on viral dynamics and transmission
- 105 potential.
- 106
- 107 Here, we present the longitudinal dynamics of SARS-CoV-2 infection in 23 individuals
- 108 infected at varying stages of vaccination (6 fully vaccinated, *i.e.* enrolled at least 14 109 days after second mRNA vaccine dose or first J&J vaccine dose; 6 partially vaccinated,
- *i.e.* not fully vaccinated but enrolled at least 14 days past first mRNA vaccine dose; and
- 111 11 newly vaccinated individuals that enrolled less than 14 days after first vaccine dose.
- (either mRNA or J&J)), captured at two study sites through daily nasal swab and saliva
- 113 collection, along with symptom reporting (**Fig 1A-C**). These individuals were primarily
- 114 infected with B.1.1.7 (Alpha) and P.1 (Gamma) variants, as enrollment in this study
- 115 concluded before the widespread circulation of Delta at the study sites (**Table 1**)
- 116



118 Figure 1: Viral dynamics in vaccinated individuals. (A) Temporal trends for the 119 saliva RTqPCR (light blue squares), nasal swab RTqPCR (dark blue dots), and positive 120 nasal swab viral culture results (tan bars) in fully vaccinated individuals that enrolled >/= 121 14 days after second mRNA vaccine dose or first J&J vaccine dose. The X axis shows 122 days since the first positive PCR result. The Y axis indicates Ct values for saliva 123 RTqPCR assay (covidSHIELD) and Cn values for nasal swab RTqPCR assay (Abbott 124 Alinity). Horizontal dashed line indicates limit of detection of RTqPCR assays. For 125 individuals at the NU study site, saliva samples were not collected thus only nasal swab 126 data are shown. (B) Same data as in (A) but for partially vaccinated individuals that 127 enrolled \geq 14 days after first mRNA vaccine dose but were not vet fully vaccinated. (C) 128 Same data as in (A) but for newly vaccinated individuals that enrolled < 14 days after 129 first mRNA or J&J vaccine dose. (D) Numbers of days that vaccinated (combined fully and partially vaccinated individuals), newly vaccinated individuals, and unvaccinated 130 131 individuals (from Ke et al.⁷) tested viral culture positive. ns, p>0.05; * p<0.05; ** p<0.01; 132 *** p<0.001. **(E)** Association between the nasal Cn values and the probability of the 133 sample being viral culture positive summarized across the vaccinated individuals, newly 134 vaccinated individuals, and unvaccinated individuals (from Ke et al.⁷). Dots indicate 135 individual viral culture results, 1 being a positive result, and 0 a negative result. The 136 solid line and the shaded area are the mean and the confidence intervals, respectively, 137 of a logistic regression fit. (F) Proportion of days post-enrollment (up to 14 days) that 138 vaccinated, newly vaccinated, and unvaccinated individuals reported no symptoms. ns, 139 p>0.05; * p<0.05; ** p<0.01; *** p<0.001. (G) Plot showing antigen FIA results from 140 days where participants tested either positive or negative by viral culture. The text inside 141 the bars indicates the percentage of antigen FIA results that were positive when 142 concurrent viral culture sample was positive or negative.

143

5 out of 6 fully vaccinated individuals remained viral culture negative throughout their
enrollment period, suggesting minimal shedding of infectious virus and little to no
transmission risk. Moreover, the 5 individuals who remained viral culture negative had
either undetectable or sporadic and low-level (generally Cn>35) viral genome loads in
the nasal compartment.

149

150 Interestingly, in 2 (487941 and 487250) of the 3 viral culture negative individuals for 151 which we collected both saliva and nasal samples, viral RNA was detectable in saliva 152 for 5 to 10 days while remaining either undetectable (487941) or detectable at very low 153 level for 2 days (487250) in nasal swabs. These data suggest that in 2 of the 4 fully 154 vaccinated individuals for which both saliva and nasal swabs were collected, infection 155 was initially established within the oral cavity or other saliva-exposed tissue site and 156 was restricted from disseminating to the nasal passages. We did not observe a similar 157 restriction of virus to saliva across 60 non-vaccinated individuals that we examined in a 158 previous report⁷, suggesting that severe compartmentalization and tissue-restriction of 159 virus may be a unique feature of vaccine breakthrough infections. 160

161 The one fully vaccinated individual (475670) that did test viral culture positive exhibited

162 highly discordant patterns of viral shedding between saliva and nasal swabs. Viral

163 genome loads expanded and declined in saliva samples over the first week of sample

164 collection while remaining very low or undetectable in nasal swabs. At day nine post-

165 enrollment, viral genome loads suddenly spiked in nasal samples and the individual

166 began testing viral culture positive. This pattern is consistent with initial containment of

167 the virus in saliva-associated tissue, followed by eventual viral breakthrough and

168 dissemination to the nasal compartment.

169

170 Patterns of viral shedding in partially vaccinated individuals were more variable. Of the 6

171 individuals that were not considered fully vaccinated but enrolled ≥14 days after

receiving the first dose of mRNA vaccine, 2 only tested positive by RT-qPCR in a single

sample (out of 13 or 15 total samples) (Fig. 1B), suggesting highly restricted infection
with minimal transmission risk. In the other 3 individuals, viral shedding dynamics were

175 indistinguishable from what we previously observed in unvaccinated individuals⁷, and 2

176 of these 3 tested viral culture positive on at least one day (**Fig. 1B**). Of the 11

177 individuals that enrolled within 14 days of receiving their first vaccine dose ("newly

178 vaccinated"), most appeared similar to unvaccinated individuals with the exception of

179 three that appeared to exhibit restricted shedding (Fig. 1C). These data are consistent

180 with individual variation in the onset and magnitude of vaccine-mediated protection.

181

182 We directly compared duration of infectious virus shedding between fully and partially

183 vaccinated individuals (combined here as "vaccinated" due to low numbers), newly

184 vaccinated individuals, and unvaccinated individuals from our previous study (Fig. 1D)⁷.

185 The total numbers of days that vaccinated individuals tested viral culture positive was

significantly fewer than both newly vaccinated and unvaccinated groups, indicating that

187 vaccination significantly reduces infectious virus shedding.

188

189 We also examined whether the relationship between nasal swab Cn value and viral 190 culture status differed in vaccinated (both fully and partially), newly vaccinated, and 191 unvaccinated individuals (from Ke et al⁷) (**Fig. 1E**). For samples with Cn values below 192 27, we found that the probability of being viral culture positive was lower for samples 193 coming from vaccinated individuals versus newly vaccinated and unvaccinated 194 individuals. These data suggest that for a given viral genome load (as measured by RTqPCR), vaccinated individuals may be less infectious than unvaccinated individuals, 195 196 consistent with a recent report examining Delta breakthrough infections⁸. However, we 197 must emphasize that this difference is not statistically significant, potentially due to both 198 the relatively small number of samples from vaccinees and the fact that only 6 out of 12 199 individuals included in the vaccinated group were fully vaccinated at the time of 200 enrollment. Regardless, these data further illustrate that Ct/Cn values cannot be used 201 as a simple surrogate for infectious potential.

202

We next examined whether there were any differences in self-reported symptoms between vaccinated and unvaccinated individuals (using the 60 unvaccinated individuals previously reported⁷) (**Fig. 1F**). A Poisson regression shows that those who received at least one vaccine dose had significantly more days with no reported symptoms than the unvaccinated (p<0.0001). The mean proportion of study days with no symptoms was 0.74 in the vaccinated group dose compared with 0.37 in the

209 unvaccinated group (range: 0 to 1 for both groups).

210

Finally, we examined the relationship between viral culture and antigen FIA results in vaccinated (fully plus partially) and newly vaccinated individuals (Fig 1G). We observed

- that vaccinated and newly vaccinated participants tested positive by antigen FIA on
- 214 78% and 85% of the days on which they also tested positive by viral culture, suggesting
- that antigen FIA can be used to identify vaccine breakthrough infections with high
- 216 transmission risk, especially if used as part of a serial screening program⁹. These
- 217 results are consistent with our previous results in unvaccinated individuals as well as
- earlier cross-sectional studies examining the relationship between antigen tests
- 219 positivity and infectious virus shedding^{7,10,11}.
- 220

221 This study has several limitations that must be considered. First, the study cohort size is 222 small, thus making it hard to draw firm quantitative conclusions. Second, our study 223 cohort is biased towards breakthrough infections that were detected in our on-campus 224 screening programs (saliva-based RTqPCR at UIUC, nasal swab-based LAMP assay at 225 NU). Finally, enrollment in this study concluded before the arrival of the Delta variant at 226 either study site. It remains unclear how well the effects of vaccination on viral infection 227 dynamics that we describe apply to Delta variant breakthrough infections, given the 228 unique features¹² and enhanced transmissibility¹³ of this variant relative to the viruses 229 we captured here.

230

Overall, our data suggest that vaccinated individuals are less likely to be shedding

- infectious virus at a given viral genome load and shed for a shorter period of time compared to unvaccinated and report fewer days of symptoms. We also show that
- 234 some breakthrough infections in fully vaccinated individuals may be tissue restricted
- and only detectable through saliva screening. The clinical implications of
- 236 compartmentalization are that testing (RT-PCR or antigen) based on nasal swabs may
- 237 underestimate the true number of breakthrough infections, and that an important role of
- vaccine-elicited immunity may be restricting viral dissemination and thus limiting
- symptom severity and transmission potential. These data also further support a role for
- the oral cavity or other saliva-associated tissue sites as an initial site for SARS-CoV-2 infection prior to dissemination and replication of the virus in nasal passages in some
- 241 injection prior to dissemination and replication of the virus in hasal passages in some
- individuals. Altogether, this study provides a set of high resolution data that ratify the
- role of the current SARS-CoV-2 vaccines not only in reducing severity of the disease,
- but also the infectiousness of individuals with breakthrough infections.

246 METHODS

This study was approved by the Western Institutional Review Board, and all participantsprovided informed consent.

249

250 Participants

251 University of Illinois at Urbana-Champaign (UIUC) enrollment site: All on-campus

- students and employees of the University of Illinois at Urbana-Champaign were required
- to submit saliva for RTqPCR testing every 2-4 days as part of the SHIELD campus
- surveillance testing program¹⁴. Those testing positive were instructed to isolate and
- 255 were eligible to enroll in this study for a period of 24 hours following receipt of their

256 positive test result. Close contacts of individuals who test positive (particularly those co-257 housed with them) were instructed to guarantine and were eligible to enroll for up to 5 258 days after their last known exposure to an infected individual. All participants were also 259 required to have received a negative saliva RTqPCR result 7 days prior to enrollment. 260

- 261 Northwestern University (NU) enrollment site: All NU on-campus students were 262 required to have nasal swab samples collected for LAMP testing once per week as part 263 of the campus surveillance program. Those testing positive were required to go in the 264 Health Service Quarantine and Isolation (QI) program for isolation. They were eligible 265 for enrollment in this study within 24 hours of going into isolation. Close contacts of 266 individuals who tested positive (particularly those co-housed with them) were also 267 entered in the NU QI program. They were instructed to quarantine and were eligible to 268 enroll in this study for up to 5 days after their last known exposure to an infected 269 individual. All participants were also required to have received a negative nasal swab 270 LAMP assay result 7 days prior to enrollment.
- 271

272 Individuals were recruited via either a link shared in an automated text message 273 providing isolation information sent within 30 minutes of a positive test result, a call from

274 a study recruiter, or a link shared by an enrolled study participant or included in

275 information provided to all guarantining close contacts. In addition, signs/flyers were

276 used at each testing location and a website was available to inform the community about the study.

277 278

279 Participants were required to be at least 18 years of age, have a valid university ID, 280 speak English, have internet access, and live within 8 miles of the university campus. 281 After enrollment and consent, participants completed an initial survey to collect 282 information on demographics, vaccination status, prior infection history, and health 283 history and were provided with sample collection supplies. Participants who tested 284 positive prior to enrollment or during guarantine were followed for up to 14 days. 285 Quarantining participants who continued to test negative by saliva RTgPCR (UIUC) or 286 nasal swab RTqPCR (NU) were followed for up to 7 days after their last exposure. All 287 participants' data and survey responses were collected in the Eureka digital study 288 platform.

289

290 Sample collection

- 291 Each day, participants were remotely observed by trained study staff collecting: 292
 - 1. 2 mL of saliva into a 50mL conical tube (UIUC study site only).
 - 2. 1 nasal swab from a single nostril using a foam-tipped swab that was placed within a dry collection tube.
 - 3. 1 nasal swab from the other nostril using a flocked swab that was subsequently placed in a collection vial containing viral transport media (VTM).
- 296 297

293

294

295

298 The order of nostrils (left vs. right) used for the two different swabs was randomized. For 299 nasal swabs, participants were instructed to insert the soft tip of the swab at least 1 cm 300 into the indicated nostril until they encountered mild resistance, rotate the swab around

301 the nostril 5 times, leaving it in place for 10-15 seconds. After daily sample collection, participants completed a symptom survey. A courier collected all participant samples
 within 1 hour of collection using a no-contact pickup protocol designed to minimize

304 courier exposure to infected participants.

305

306 Saliva RTqPCR

- After collection, saliva samples were stored at room temperature and RTqPCR was run within 12 hours of initial collection. The protocol for the covidSHIELD direct saliva-to-RTqPCR assay used has been detailed previously^{14,15}. In brief, saliva samples were heated at 95°C for 30 minutes, followed by the addition of 2X Tris/Borate/EDTA buffer (TBE) at a 1:1 ratio (final concentration 1X TBE) and Tween-20 to a final concentration
- of 0.5%. Samples were assayed using the Thermo TagPath COVID-19 Combo kit
- 313 assay.
- 314

315 Antigen testing

- Foam-tipped nasal swabs were placed in collection tubes, transported with cold packs,
- and stored at 4°C overnight based on guidance from the manufacturer. The morning
- after collection, swabs were run through the Sofia SARS antigen FIA on Sofia 2 devices
- according to the manufacturer's protocol.

320

321 Nasal swab RTqPCR

- For UIUC cohort, collection tubes containing VTM and flocked nasal swabs were stored at -80°C after collection and were subsequently shipped to Johns Hopkins University for RTqPCR and virus culture testing. After thawing, VTM was aliquoted for RTqPCR and infectivity assays. One ml of VTM from the nasal swab was assayed on the Abbott Alinity per manufacturer's instructions in a College of American Pathologist and CLIAcertified laboratory. Calibration curve for Alinity assay was determined using digital droplet PCR (ddPCR) as previously described¹⁶.
- 329

330 Virus culture from nasal swabs

- Vero-TMPRSS2 cells were grown in complete medium (CM) consisting of DMEM with 10% fetal bovine serum (Gibco), 1 mM glutamine (Invitrogen), 1 mM sodium pyruvate
- (Invitrogen), 100 U/ml of penicillin (Invitrogen), and 100 μ g/ml of streptomycin
- (Invitrogen)¹⁷. Viral infectivity was assessed on Vero-TMPRSS2 cells as previously
- described using infection media (IM; identical to CM except the FBS is reduced to 2.5%)¹¹. When a cytopathic effect was visible in >50% of cells in a given well, the
- 336 2.5%)¹¹. When a cytopathic effect was visible in >50% of cells in a given well, the 337 supernatant was harvested. The presence of SARS-CoV-2 was confirmed through
- 338 RTqPCR as described previously by extracting RNA from the cell culture supernatant
- using the Qiagen viral RNA isolation kit and performing RTqPCR using the N1 and N2
- 340 SARS-CoV-2-specific primers and probes in addition to primers and probes for human
- RNaseP gene using synthetic RNA target sequences to establish a standard curve¹⁸.
- 342

343 Viral genome sequencing and analysis

- Viral RNA was extracted from 140 uL of heat inactivated (30 minutes at 95°C, as part of
- protocol detailed in¹⁵) saliva samples using the QIAamp viral RNA mini kit (QIAGEN).
- 346 100ng of viral RNA was used to generate cDNA using the SuperScript IV first strand
- 347 synthesis kit (Invitrogen). Viral cDNA was then used to generate sequencing libraries

348 using the Swift SNAP Amplicon SARS CoV2 kit with additional coverage panel and 349 unique dual indexing (Swift Biosciences) which were sequenced on an Illumina 350 Novaseq SP lane. Data were run through the nf-core/viralrecon workflow (https://nf-351 co.re/viralrecon/1.1.0), using the Wuhan-Hu-1 reference genome (NCBI accession 352 NC 045512.2). Swift v2 primer sequences were trimmed prior to variant analysis from 353 iVar version 1.3.1 (https://genomebiology.biomedcentral.com/articles/10.1186/s13059-354 018-1618-7) retaining all calls with a minimum allele frequency of 0.01 and higher. Viral 355 lineages were called using the Pangolin tool (https://github.com/cov-lineages/pangolin) 356 version 2.4.2, pango version 1.2.6, and the 5/19/21 version of the pangoLEARN model. 357

358 **Acknowledgments.** We wish to thank Shumon Ahmed, Carly Bell, Nate Bouton, 359 Shannon Bradley, Callie Brennen, Justin Brown, Coleco Buie, Emmaline Cler, Gary 360 Cole, Trey Coleman, Alastair Dunnett, Darci Edmonson, Lauren Engels, Savannah 361 Feher, Kelsey Fox, Lexi Freeman, Stacy Gloss, Yesenia Gonzalez, Montez Harris, 362 Darcy Henness, Dan Hiser, Ayeshah Hussain, Daryl Jackson, Junko Jarrett, Michael 363 Jenkins, Kalombo Kalonii, Svntvche Kanku, Steven Krauklis, Marv Krouse, Elmore 364 Leshoure, Joe Lewis, Maggie Li, Angel Lopez, Guadalupe Lopez, Emily Luna, Chun 365 Huai Luo, Colby Mackey, Skyler McLain, Yared Berhanu Melesse, Madison O'Donnell, 366 Savanna Pflugmacher, Denver Piatt, Skyler Pierce, Jessica Quicksall, Gina Quitanilla, 367 Crystal Reinhart, Ameera Samad, MacKenzie Scroggins, Monigue Settles, Macie Sinn, 368 Pete Varney, Evette Vlach, Raeshun Williams-Chatman, Jagadeesh Yedetore, and 369 Todd Young for their efforts supporting recruitment, enrollment, logistics, and/or sample 370 collection and processing at the UIUC study site.

371

We also wish to thank Kate Klein, Amelia Kelly, Nour Sayegh, Michael Govern, 372 373 Mackenzie Furnari-Stickney, Sara Caudillo, Elizabeth Christain, Kristen Weber, James 374 Jackson, Sowmya Ravi, Jack Novotny, Reno Stephens, Benjamin Engebretson, 375 Patricia Helbin, Jessica Orozco, Alema Jackson, Adriana Quintatna, Hiba Abbas, Rana 376 Saber, Eric Fickes, Matthew Butzler, Rocio Avila, Abhishek Agarwal, Robin Kim, William 377 Zeng, Tosin Odumuye, Kirsten Knapton, Melissa Mongrella, Michael Newcomb, 378 Kenyetta Sims, and Carol Govern for their efforts supporting recruitment, enrollment, 379 logistics, and/or sample collection and processing at the NU study site.

380

381 We also thank Jeffrey Olgin, Noah Peyser, and Xochitl Butcher for assistance with the 382 Eureka platform, Michelle Lore for assistance with REDcap, Melanie Loots for 383 assistance with administration, Gillian Snyder for assistance in development of study 384 protocols and logistics, and Erin Iturriaga and Jue Chen for study protocol development. 385 Finally, we are grateful to Dr. Alvaro Hernandez and Ms. Chris Wright of the DNA 386 Services Lab within the Roy J. Carver Biotechnology Center for expert assistance in 387 establishment of a SARS-CoV-2 genomic sequencing protocol. Vero-TMPRSS2 cells 388 were kindly provided by the National Institute of Infectious Diseases, Japan. Sofia 2 389 devices and associated supplies were provided to Carle Foundation Hospital by Quidel, 390 however Quidel played no role in the design of the study or the interpretation or 391 presentation of the data.

392

- **Funding.** This work was supported by the National Heart, Lung, and Blood Institute at
- the National Institutes of Health [3U54HL143541-02S2] through the RADx-Tech
- 395 program. This work was also supported by the National Institute of Biomedical Imaging
- and Bioengineering through the Center for Innovation in Point of Care Technologies for
- 397 HIV/AIDS at Northwestern (C-THAN) [3U54EB027049-02S1]. The views expressed in
- this manuscript are those of the authors and do not necessarily represent the views of
- the National Institute of Biomedical Imaging and Bioengineering; the National Heart,
- Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health and Human Services.
- 401 He 402

403 **REFERENCES**

- Yewdell, J. W. Individuals cannot rely on COVID-19 herd immunity: Durable
 immunity to viral disease is limited to viruses with obligate viremic spread. *PLoS Pathog* 17, e1009509 (2021).
- 407 2. Prunas, O. et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2
 408 to household contacts in Israel.
- 409 http://medrxiv.org/lookup/doi/10.1101/2021.07.13.21260393 (2021)
- 410 doi:10.1101/2021.07.13.21260393.
- 3. Riemersma, K. K. *et al. Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant.*http://medrxiv.org/lookup/doi/10.1101/2021.07.31.21261387 (2021)
 doi:10.1101/2021.07.31.21261387.
- 415 4. Chia, P. Y. *et al. Virological and serological kinetics of SARS-CoV-2 Delta variant*416 *vaccine-breakthrough infections: a multi-center cohort study.*417 http://medrxiv.org/lookup/doi/10.1101/2021.07.28.21261295 (2021)
- 418 doi:10.1101/2021.07.28.21261295.
- 419 5. Luo, C. H. et al. Infection with the SARS-CoV-2 Delta Variant is Associated with
 420 Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated
 421 and Vaccinated Individuals.
- 422 http://medrxiv.org/lookup/doi/10.1101/2021.08.15.21262077 (2021)
 423 doi:10.1101/2021.08.15.21262077.
- 424 6. Kennedy-Shaffer, L., Kahn, R. & Lipsitch, M. *Estimating vaccine efficacy against* 425 *transmission via effect on viral load*.
- 426 http://medrxiv.org/lookup/doi/10.1101/2021.05.03.21256556 (2021)
 427 doi:10.1101/2021.05.03.21256556.
- 428 7. Ke, R. et al. Daily sampling of early SARS-CoV-2 infection reveals substantial
 429 heterogeneity in infectiousness.
- 430 http://medrxiv.org/lookup/doi/10.1101/2021.07.12.21260208 (2021)
 431 doi:10.1101/2021.07.12.21260208.
- 432 8. Shamier, M. C. *et al. Virological characteristics of SARS-CoV-2 vaccine*433 *breakthrough infections in health care workers.*
- 434 http://medrxiv.org/lookup/doi/10.1101/2021.08.20.21262158 (2021)
- 435 doi:10.1101/2021.08.20.21262158.

- 436 9. Smith, R. L. *et al.* Longitudinal assessment of diagnostic test performance over the
 437 course of acute SARS-CoV-2 infection. *The Journal of Infectious Diseases* jiab337
 438 (2021) doi:10.1093/infdis/jiab337.
- 439 10. Monel, B. *et al. Release of infectious virus and cytokines in nasopharyngeal swabs*440 *from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.*441 http://medrxiv.org/lookup/doi/10.1101/2021.05.20.21257393 (2021)
 442 doi:10.1101/2021.05.20.21257393 (2021)
- 442 doi:10.1101/2021.05.20.21257393.
- 11. Pekosz, A. *et al.* Antigen-Based Testing but Not Real-Time Polymerase Chain
 Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral
 Culture. *Clin Infect Dis* (2021) doi:10.1093/cid/ciaa1706.
- 446 12. Liu, Y. *et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha*447 *variant.* http://biorxiv.org/lookup/doi/10.1101/2021.08.12.456173 (2021)
 448 doi:10.1101/2021.08.12.456173.
- 449 13. Kang, M. et al. Transmission dynamics and epidemiological characteristics of Delta
 450 variant infections in China.
- 451 http://medrxiv.org/lookup/doi/10.1101/2021.08.12.21261991 (2021) 452 doi:10.1101/2021.08.12.21261991.
- 453 14. Ranoa, D. R. E. *et al. Mitigation of SARS-CoV-2 Transmission at a Large Public*454 *University.* http://medrxiv.org/lookup/doi/10.1101/2021.08.03.21261548 (2021)
 455 doi:10.1101/2021.08.03.21261548.
- 456 15. Ranoa, D. R. E. *et al. Saliva-Based Molecular Testing for SARS-CoV-2 that*457 *Bypasses RNA Extraction*. http://biorxiv.org/lookup/doi/10.1101/2020.06.18.159434
 458 (2020) doi:10.1101/2020.06.18.159434.
- 459 16. Gniazdowski, V. *et al.* Repeat COVID-19 Molecular Testing: Correlation of SARS460 CoV-2 Culture with Molecular Assays and Cycle Thresholds. *Clin Infect Dis* (2020)
 461 doi:10.1093/cid/ciaa1616.
- 462 17. Matsuyama, S. *et al.* Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing
 463 cells. *Proc Natl Acad Sci U S A* **117**, 7001–7003 (2020).
- 464 18. Waggoner, J. J. *et al.* Triplex Real-Time RT-PCR for Severe Acute Respiratory
 465 Syndrome Coronavirus 2. *Emerg. Infect. Dis.* 26, 1633–1635 (2020).

466